

# Role Of Prostate Specific Antigen Psa In Patholog

Eventually, you will totally discover a other experience and skill by spending more cash. nevertheless when? reach you acknowledge that you require to get those every needs behind having significantly cash? Why dont you attempt to get something basic in the beginning? Thats something that will guide you to comprehend even more roughly speaking the globe, experience, some places, behind history, amusement, and a lot more?

It is your categorically own epoch to do its stuff reviewing habit. accompanied by guides you could enjoy now is **role of prostate specific antigen psa in patholog** below.

*Clinical Chemistry, Immunology and Laboratory Quality Control* - Amitava Dasgupta 2013-12-02  
All pathology residents must have a good command of clinical chemistry, toxicology, immunology, and laboratory statistics to be successful pathologists, as well as to pass the American Board of Pathology examination. Clinical chemistry, however, is a topic in which many senior medical students and pathology residents face challenges. Clinical Chemistry, Immunology and Laboratory Quality Control meets this challenge head on with a clear and easy-to-read presentation of core topics and detailed case studies that illustrate the application of clinical chemistry knowledge to everyday patient care. This basic primer offers practical examples of how things function in the pathology clinic as well as useful lists, sample questions, and a bullet-point format ideal for quick pre-Board review. While larger textbooks in clinical chemistry provide highly detailed information regarding instrumentation and statistics, this may be too much information for students, residents, and clinicians. This book is designed to educate senior medical students, residents, and fellows, and to "refresh" the knowledge base of practicing clinicians on how tests are performed in their laboratories (i.e., method principles, interferences, and limitations). Takes a practical and easy-to-read approach to understanding clinical chemistry and toxicology Covers all important clinical information found in larger textbooks in a more succinct and easy-to-understand manner Covers essential concepts in instrumentation and statistics in such a way that fellows and clinicians understand the methods without having to become specialists in the field Includes chapters on drug-herb interaction and pharmacogenomics, topics not covered by textbooks in the field of clinical chemistry or laboratory medicine

**Prostate Cancer Prevention** - Jack Cuzick 2014-02-15

Prostate cancer is by far the most common cancer in men and the second leading cause of death due to cancer. It comprises a mixed group of tumours displaying varying clinical behaviour: while some have a very aggressive course, others are rather indolent. Prevention of prostate cancer and discrimination between aggressive and indolent forms are important clinical goals and the acquisition of significant new evidence on means of achieving these aims makes this book particularly timely. A wide range of topics are covered by leading authorities in the field. The biology and natural history of prostate cancer are reviewed and the role of lifestyle and dietary factors, assessed. Detailed attention is paid to risk prediction biomarkers and to the role of novel high-throughput nucleic acid-based technologies in improving risk prediction and thereby allowing tailored approaches to cancer prevention. Potential means of chemoprevention of prostate cancer are also reviewed in depth, covering the very positive new data on the impact of aspirin as well as evidence regarding 5 $\alpha$ -reductase inhibitors, DFMO and lycopene. Guidance is provided on the differentiation of aggressive from indolent disease and the policy and research implications of recent findings are examined. This book will be of interest to both clinicians and researchers.

*A Crash Course on Prostate Cancer* - Lynne Rosenberg 2006-09

Sometimes a woman just needs to hear certain things from another woman. And one of those times is when your husband may have prostate cancer. When author Lynne Rosenberg, a registered nurse and wife of a medical doctor, began to research this disease after her husband Mark was diagnosed, she found very little useful information about the day-to-day decisions and

difficulties they would face. Scrambling to decipher test results, procedures, medications, and side effects, she discovered that each woman faces this process as if facing uncharted territory. Prostate cancer involves the physical and mental mechanisms that in some ways define both masculinity and intimacy, and Rosenberg confronts these subjects with refreshing frankness. After devoting more than a year to her husband's illness, treatment, and recovery, she has organized her experience into a readable and rational discussion that can help prepare women to deal with everything for which she herself had no preparation. While not intended to replace the doctor, nurse, or counselor in the management of this disease, *A Crash Course on Prostate Cancer: From One Woman's Perspective* will provide you with the support that only another woman can give.

*Adenocarcinoma of the Prostate* - Andrew W. Bruce 2012-12-06

Carcinoma of the prostate increasingly dominates the attention of urologists for both scientific and clinical reasons. The search for an explanation and the prediction of the variable behaviour of the malignant prostatic cell continues unabated. The search for more precise tumour staging and more effective treatment is equally vigorous. Editors Andrew Bruce and John Trachtenberg have assembled acknowledged leaders in prostate cancer to present those areas of direct interest to the clinician. There are a number of other topics that might have been considered but most of these, such as experimental tumour models or biochemical factors affecting cell growth, still lack immediate application for the clinician. Carcinoma of the prostate continues to have its highest incidence in the western world, and the difference in comparison with the incidence in the Far East appears to be real and not masked by diagnostic or other factors. A number of other epidemiological aspects need careful analysis: Is the incidence increasing? Is the survival improving? Is the prognosis worse in the younger patient? Epidemiological data are easily misused and misinterpreted so that a precise analysis of the known facts makes an important opening chapter to this book.

*Fundamentals of Cancer Prevention* - David Alberts 2008-09-24

An authoritative work that provides a detailed review of the current status of cancer prevention and control practice and research. This volume is an essential reference guide and tool for primary care physicians, the research community and students. Written as a collaborative work by the faculty of the nationally renowned Cancer Prevention and Control Program at the Arizona Cancer Center, this book brings together the expertise of specialists in the field of cancer prevention and control to provide the medical and research community that does not specialize in this field with insight to the disciplines of cancer prevention and control.

*Prostate Cancer* - Rene Sotelo 2014-11-20

Understanding prostate diseases without the proper and reliable guidance can be overwhelming because the internet, television and print media saturate us with information ranging from scientific studies across the world to inspiring stories from cancer survivors to many myths and rumors. How do we interpret all that information? This book intends to help patients and their families to know and understand their diagnosis. Once this has been established, the reader can confidently determine the best choice of treatment, resting assured that the guidance in this book adheres to current international medical standards and has been influenced by the authors' many

years of professional experiences. The editors aim to transmit, in a simple and precise manner, only relevant and necessary information to help patients and families that have been diagnosed with prostate diseases.

**Lateral Flow Immunoassay** - Raphael Wong 2008-12-16

Due to the simplicity, relative accuracy, fast result reporting, and user-friendliness of lateral flow immunoassay, its use has undergone tremendous growth in the diagnostic industry in the last few years. Such technology has been utilized widely and includes pregnancy and woman's health determination, cardiac and emergency conditions monitoring and testing, infectious disease including Flu screening, cancer marker screening, and drugs abuse testing. This book covers the scope of utilization, the principle of the technology, the patent concerns, information on the development and production of the test device and specific applications will be of interest to the diagnostic industry and the general scientific community.

Progress in Molecular Biology and Translational Science - 2019-03-22

Glycans and Glycosaminoglycans as Clinical Biomarkers and Therapeutics - Part A, Volume 162 in the Progress in Molecular Biology and Translational Science series provides informative monographs on a variety of research topics related to Glycans and glycosaminoglycans as clinical biomarkers and therapeutics. Topics in this update include Glycan-based Biomarkers for Diagnosis of Cancers and Other Diseases: Past, Present and Future, Desialylation in Diseases and its Application in Diagnostic and Therapeutic Development, Proteoglycans as Miscommunication Biomarkers for Cancer Diagnosis, Fucosylation in Cancer Biology and Its Clinical Applications, Retrospective Analysis of Glycan-Related Biomarkers Based on Clinical Laboratory Data in Two Medical Centers, and many related topics. Includes comprehensive coverage of molecular biology Presents ample use of tables, diagrams, schemata and color figures to enhance the reader's ability to rapidly grasp the information provided Contains contributions from renowned experts in the field

**PSA and Prostate Cancer Research** - Savita Yadav 2010-01-01

The incidence of prostate cancer in men is very high worldwide, being the most commonly diagnosed cancer in the USA. It is the second most common cause of deaths of all types of cancers and the incidence and risk rate is much higher in developed world than underdeveloped regions. Also, aging enhances the risk of prostate cancer as it is very rare in men under the age of 40 while it is very frequent over age of 65. The digital rectal examination (DRE) and Prostate specific antigen (PSA) blood test are two important ways to diagnose prostate cancer. This new book presents and discusses the possible role of PSA in prostate cancer.

**The Immunoassay Handbook** - David Wild 2013-01-21

The fourth edition of The Immunoassay Handbook provides an excellent, thoroughly updated guide to the science, technology and applications of ELISA and other immunoassays, including a wealth of practical advice. It encompasses a wide range of methods and gives an insight into the latest developments and applications in clinical and veterinary practice and in pharmaceutical and life science research. Highly illustrated and clearly written, this award-winning reference work provides an excellent guide to this fast-growing field. Revised and extensively updated, with over 30% new material and 77 chapters, it reveals the underlying common principles and simplifies an abundance of innovation. The Immunoassay Handbook reviews a wide range of topics, now including lateral flow, microsphere multiplex assays, immunohistochemistry, practical ELISA development, assay interferences, pharmaceutical applications, qualitative immunoassays, antibody detection and lab-on-a-chip. This handbook is a must-read for all who use immunoassay as a tool, including clinicians, clinical and veterinary chemists, biochemists, food technologists, environmental scientists, and students and researchers in medicine, immunology and proteomics. It is an essential reference for the immunoassay industry. Provides an excellent revised guide to this commercially highly successful technology in diagnostics and research, from consumer home pregnancy kits to AIDS testing. [www.immunoassayhandbook.com](http://www.immunoassayhandbook.com) is a great resource that we put a lot of effort into. The content is designed to encourage purchases of single chapters or the

entire book. David Wild is a healthcare industry veteran, with experience in biotechnology, pharmaceuticals, medical devices and immunodiagnostics, which remains his passion. He worked for Amersham, Eastman-Kodak, Johnson & Johnson, and Bristol-Myers Squibb, and consulted for diagnostics and biotechnology companies. He led research and development programs, design and construction of chemical and biotechnology plants, and integration of acquired companies. Director-level positions included Research and Development, Design Engineering, Operations and Strategy, for billion dollar businesses. He retired from full-time work in 2012 to focus on his role as Editor of The Immunoassay Handbook, and advises on product development, manufacturing and marketing. Provides a unique mix of theory, practical advice and applications, with numerous examples Offers explanations of technologies under development and practical insider tips that are sometimes omitted from scientific papers Includes a comprehensive troubleshooting guide, useful for solving problems and improving assay performance Provides valuable chapter updates, now available on [www.immunoassayhandbook.com](http://www.immunoassayhandbook.com)

*Multidisciplinary Management of Prostate Cancer* - Vincenzo Gentile 2014-04-11

Prostate cancer is the most common neoplasm in men and its management is very complex, in terms of both diagnosis and treatment. In recent years the value of multidisciplinary management within a prostate cancer unit has been increasingly recognized. Such a multidisciplinary approach within a specialized unit involves a variety of specialists, including urologists, oncologists, radiotherapists, radiologists and pathologists. This book describes in detail the advantages of multidisciplinary management of prostate cancer. It opens by explaining the nature of the required multidisciplinary team and the potential benefits of the prostate cancer unit as a structure for the delivery of specialist multidisciplinary care. Epidemiological aspects favoring multidisciplinary management are described and each element of care within the context of the prostate cancer unit is then discussed; also has been described the role of advanced imaging (Multiparametric MRI) in the management of PCa. Early diagnosis, risk classification, treatment decision making, surgery, radiotherapy, medical therapies and health care support are all fully considered. This book will be informative and enlightening for all who are involved in the management of patients with prostate cancer.

**Harms of Prostate-specific Antigen (PSA) Screening in Prostate Cancer** - Jennifer Fergenbaum 2015

Invasion of the Prostate Snatchers: Revised and Updated Edition - Mark Scholz 2021-08-31

An indispensable map through the medical minefield of prostate cancer, revised and updated with the latest developments in treatment options. Every year almost a quarter of a million confused and frightened American men are tossed into a prostate cancer cauldron stirred by salespeople representing a multibillion-dollar industry. Patients are too often rushed into a radical prostatectomy, a major operation that rarely prolongs life and more than half the time leaves them impotent. Invasion of the Prostate Snatchers argues that close monitoring—active surveillance rather than surgery or radiation—should be the initial treatment approach for many men at the low- and intermediate-risk stages. In a unique collaboration, doctor and patient provide a wholly new perspective on managing this disease. Ralph Blum's account of his personal struggle, together with Dr. Mark Scholz's presentation of new scientific advances, offers convincing evidence that this noninvasive approach can be crucial in preventing tens of thousands of men from being overtreated each year. This revised and updated second edition: - Highlights the latest prostate cancer treatment options that preserve erectile and urinary function while prolonging lifespan -Establishes updated protocol for how to accurately interpret high prostate-specific antigen (PSA) while avoiding the invasive, dangerous random biopsy -Recounts true patient stories that accurately represent the hurdles today's patients face while navigating a prostate cancer diagnosis -Introduces the latest evidence in the radiation vs. radical prostatectomy debate -Presents the latest thinking on diet and exercise for men with prostate cancer

**Fast Facts: Prostate Cancer** - Roger S. Kirby 2017-03-08

Prostate cancer is unusual among solid tumors in that the majority of affected men die with, rather than of, the disease. This presents many challenges to healthcare professionals and patients in terms of deciding if, when and how to intervene in order to control tumor growth and spread, thereby extending survival but without compromising quality of life. This is the ninth edition of 'Fast Facts: Prostate Cancer' since 1996, testament to the rapid changes in the field and the steadily improving outlook for patients. This new edition provides many key updates: • the Gleason grade grouping, which has valuable prognostic value • nomograms to evaluate risk • our rapidly expanding understanding of the genetics and underlying pathogenesis of prostate cancer and the development of genomic tests to help identify those at greatest risk of developing clinically significant disease • the continuing debate about the role of PSA in the screening, detection and monitoring of prostate cancer • advances in imaging techniques, particularly multiparametric MRI, which is improving the accuracy of biopsy and reducing the numbers of negative biopsies • the roles of drugs, surgery and radiotherapy in the treatment of prostate cancer at different stages, and our ever-improving understanding of when and how best to intervene, aided by improving understanding of the risk factors for disease progression. Primarily intended for primary care providers, specialist nurses, junior doctors and allied healthcare professionals, this highly readable resource provides a comprehensive overview of prostate cancer, enabling fully informed discussions with patients about this complex disease. Contents: • Epidemiology and pathophysiology • Diet, lifestyle and chemoprevention • Screening and early detection • Diagnosis, staging and prognostic indicators • Management of clinically localized disease • Managing recurrence after initial therapy • Management of metastatic prostate cancer • Management of castrate-resistant prostate cancer • Survivorship and treatment complications  
**Prostate-specific Antigen (PSA)-based Population Screening for Prostate Cancer** - G. Pron 2015

**Clinical Oncology** - Martin D. Abeloff 2000-01

A must-have reference, this new edition provides practical information on treatment guidelines, details of diagnosis and therapy, and personal recommendations on patient management from experts in the field. Consistently formatted chapters allow for a user-friendly presentation for quick access of key information by the practicing clinician. Completely updated, this new edition includes all of the latest developments in treatment strategies of medical, surgical and radiation oncologists.

Conspiracy of Hope - Renee Pellerin 2018-10-02

For decades, women have been told that mammograms save lives. Yet many scientists say that this is in fact not true. Conspiracy of Hope reveals how breast cancer screening was introduced in the US before there was any good evidence it made any difference, and an unfounded belief in early detection caught on quickly in Canada and other developed countries. Today the evidence is starkly clear. Screening does more harm than good. Still women, and their doctors, continue to buy into a myth perpetuated by greed, fear, and wishful thinking. Conspiracy of Hope illustrates how a vortex of interests came together to make breast screening standard medical practice and why it's so hard to persuade them they are wrong. The radiologists, the imaging machinery manufacturers, and the pink ribbon charities are all part of that story. It is a tale of back-stabbing and intrigue, of exploiting fear and hope, while distorting and misrepresenting the evidence. Or simply ignoring it.

*Prostate Specific Antigen* - Michael K. Brawer 2001-06-29

This state-of-the-art reference provides a comprehensive review of prostate specific antigen (PSA) and related prostate markers-examining velocity, density, and age-specific reference ranges for increased sensitivity in PSA tumor identification and selection of patient therapies. Supplemented with helpful drawings, photographs, and tables that reinforce and clarify essential issues! Considering PSA as a monitor for cancer, Prostate Specific Antigen explores PSA levels during

radiation, chemotherapy, and hormone therapy treatments increased PSA levels in older men the effect of acute urinary retention, acute bacterial prostatitis, and benign prostatic hyperplasia on PSA concentration levels and more! With contributions by over 30 internationally distinguished experts and containing nearly 2000 timely references, Prostate Specific Antigen is an essential tool for all urologists and urologic surgeons; medical, urologic, and radiation oncologists; pathologists; clinical chemists and biochemists; primary care physicians; and fellows, residents, and medical students in these disciplines.

*Molecular Biology of Prostate Cancer* - Manfred Wirth 1998-01-01

**Encyclopedia of Cancer** - Manfred Schwab 2008-09-23

This comprehensive encyclopedic reference provides rapid access to focused information on topics of cancer research for clinicians, research scientists and advanced students. Given the overwhelming success of the first edition, which appeared in 2001, and fast development in the different fields of cancer research, it has been decided to publish a second fully revised and expanded edition. With an A-Z format of over 7,000 entries, more than 1,000 contributing authors provide a complete reference to cancer. The merging of different basic and clinical scientific disciplines towards the common goal of fighting cancer makes such a comprehensive reference source all the more timely.

**Prostate Specific Antigen and Prostate Cancer** - Sudhir Isharwal 2011

Prostate cancer (PCa) is a disease with high incidence and prevalence. Early detection of PCa has been an area for research to decrease its morbidity and mortality. The discovery of prostate specific antigen (PSA) revolutionised screening of PCa, which was largely dependent on detection of prostatic acid phosphatase and digital rectal examination. Several leading organisations and cancer societies, based on present evidence, have published their recommendations for its use in detection and monitoring of PCa. There has been difference in opinions on its appropriate threshold value to recommend prostate biopsy and benefits on health outcomes due to its use in screening. This book presents and discusses current research in the study of PCa and its role in the screening of prostate cancer.

**Prostatic Disorders** - David F. Paulson 1989

Evidence-based Urology - Philipp Dahm 2018-07-02

An updated and revised resource to evidence-based urology information and a guide for clinical practice The revised and updated second edition of Evidence-Based Urology offers the most current information on the suitability of both medical and surgical treatment options for a broad spectrum of urological conditions based on the best evidence available. The text covers each of the main urologic areas in specific sections such as general urology, oncology, female urology, trauma/reconstruction, pediatric urology, etc. All the evidence presented is rated for quality using the respected GRADE framework. Throughout the text, the authors highlight the most patient-important, clinical questions likely to be encountered by urologists in day-to-day practice. A key title in the "Evidence-Based" series, this revised and expanded edition of Evidence-Based Urology contains new chapters on a variety of topics including: quality improvement, seminoma, nonseminomatous germ cell tumor, penile cancer, medical prophylaxis, vesicoureteral reflux disease, cryptorchidism, prenatal hydronephrosis, and myelodysplasia. This updated resource: Offers a guide that centers on 100% evidence approach to medical and surgical approaches Provides practical recommendations for the care of individual patients Includes nine new chapters on the most recently trending topics Contains information for effective patient management regimes that are supported by evidence Puts the focus on the most important patient and clinical questions that are commonly encountered in day-to-day practice Written for urologists of all levels of practice, Evidence-Based Urology offers an invaluable treasure-trove of evidence-based information that is distilled into guidance for clinical practice.

*The Great Prostate Hoax* - Richard J. Ablin 2014-03-04

Reveals how fear-based and inaccurate testing is resulting in unnecessary high-risk surgeries, arguing that the PSA test was never intended for prostate cancer screening while sharing the stories of patients who have suffered from damaging procedures. 35,000 first printing.

Serological Cancer Markers - Stewart Sell 2012-12-06

The purpose of this book-the fourth volume of a series on Cancer Markers-is intended to provide an updated "status report" on today's use of cancer markers in the diagnosis and monitoring of cancer, with an emphasis on cancer markers detected in the serum. It has been 7 years since the publication of the last volume in this series. The 1980, 1982, and 1985 volumes covered the development of cancer markers, not only in their roles of unraveling the basic biology of cancer, but also as increasingly important players in the management of patients with cancer. During the last 7 years we have seen the application of a number of markers identified by monoclonal antibodies, as well as the beginnings of the use of genetic markers defined by molecular probes. Measurements of oncogenes in tissues or cells promise many applications for the future, but as yet, these genes have not shown to be useful as serum markers of cancer. The commercial interest in serum markers for cancer, particularly for the diagnosis and monitoring of tumor patients, is indicated in Chapter 24 by Owen, where the total worldwide market for cancer markers is projected to increase from \$148 million in 1988 to \$232 million in 1993. The degree of research interest in cancer markers is reflected in the fact that in 1988 a separate category for tumor markers was added to Index Medicus.

**Prostate Cancer** - Roger S. Kirby 2006-01-13

Written by over 250 of the world's leading urologists and uro-oncologists from the USA, Canada, UK, Austria, Belgium, Finland, France, Germany, Ireland, Italy, the Netherlands and Singapore, who tackle prostate cancer on a daily basis, this comprehensive and fully up-to-date illustrated text reference covers the etiology, pathophysiology, diagnosis, management and treatment of early and advanced prostate cancer.

**Lycopene** - V R Preedy 2019-09-10

Tomatoes have become a dietary staple for humans in many parts of the world. The characteristic deep red color of the ripe tomato fruit and related products is mainly due to lycopene. Lycopene is the predominant carotenoid in tomatoes, followed by a-carotene, b-carotene, g-carotene, and phytoene, as well as by several other minor carotenoids. Tomat

**Challenges in Prostate Cancer** - Winsor Bowsher 2008-04-15

Prostate cancer continues to be a major threat to men's health, thesecond most common cancer in men, in many countries. Therefore itis increasingly important that those faced with difficult clinicalquestions make the right decisions. Since the first volume waspublished in 2000, many debates persist but new controversies havealso emerged, reflected in the chapters of this new volume. Newauthors have been recruited to give their insight into newer areasof this controversial topic. Challenges in prostate cancer provides a series ofstate-of-the-art review articles, each of which addresses andanswers a contentious question. It includes chapters on medical andsurgical management of all stages of prostate cancer, clinicalinvestigation, epidemiology, clinical trials and basic scientificresearch and covers issues such as the genetic basis of cancer,clinical economics and influence. The authors have used their expertise to distil the availableevidence into practical advice to be used by busy urologists intheir day-to-day practice. And as well as being an overview ofcurrent practice many chapters attempt to give insights into thefuture direction of prostate cancer research and clinicalmanagement.

**Role of Prostate-specific Antigen (PSA) in Pathological Angiogenesis and Prostate Tumor Growth** - Ravikumar Aalinkeel 2012

Prostate specific antigen (PSA) is a serine protease present in an enzymatically inactive form in human serum at a concentration of nanograms/ml; serum PSA (S-PSA) is used widely as a surrogate marker in the diagnosis and management of prostate cancer (CaP). However, the vast majority of PSA produced in the prostate is secreted as active enzyme into the seminal fluid or is sequestered within the prostate tissue microenvironment. This book examines the role of the

prostate-specific antigen in prostate tumour growth.

**Prostate cancer** - Sics Editore 2014-10-01

Prostate cancer should be recognized by palpation (lumps) or prostate-specific antigen (PSA) determination in patients suffering from urinary symptoms.In addition to the plasma total PSA concentration, the ratio of free to total PSA and the PSA increase rate, also the age of the patient as well as the size and nodularity of the prostate gland are taken into account when assessing the probability of prostate cancer diagnosis and the need for further investigations. Metastatic prostate cancer should be identified.

*Precision Medicine for Investigators, Practitioners and Providers* - Joel Faintuch 2019-11-16

Precision Medicine for Investigators, Practitioners and Providers addresses the needs of investigators by covering the topic as an umbrella concept, from new drug trials to wearable diagnostic devices, and from pediatrics to psychiatry in a manner that is up-to-date and authoritative. Sections include broad coverage of concerning disease groups and ancillary information about techniques, resources and consequences. Moreover, each chapter follows a structured blueprint, so that multiple, essential items are not overlooked. Instead of simply concentrating on a limited number of extensive and pedantic coverages, scholarly diagrams are also included. Provides a three-pronged approach to precision medicine that is focused on investigators, practitioners and healthcare providers Covers disease groups and ancillary information about techniques, resources and consequences Follows a structured blueprint, ensuring essential chapters items are not overlooked

**Prostate-Specific Antigen-Based Screening for Prostate Cancer: an Evidence Update for the U. S. Preventive Services Task Force** - U. S. Department of Health and Human Services 2013-05-06

The American Cancer Society estimates that in 2011, about 241,000 men will be diagnosed with prostate cancer and 34,000 men will die from it, making it the most commonly diagnosed nonskin cancer and the second leading cause of cancer death in men. Prostate-specific antigen (PSA)-based screening programs have been advocated as a possible means to reduce the mortality rate, as the test can detect asymptomatic, early-stage tumors. Beginning in the 1990s, utilization of the PSA test became widespread in U.S. clinical practice; data from nationally representative surveys and community primary care clinics consistently show that the majority of American men aged 50 years and older receive regular PSA tests. This evidence update summarizes new and previously reviewed randomized controlled trials, systematic reviews, and meta-analyses to answer the following key questions: 1) Does PSA-based screening decrease prostate cancer-specific or all-cause mortality? and 2) What are the harms of PSA-based screening for prostate cancer? "PSA-based screening" is defined as a screening program for prostate cancer in asymptomatic men that incorporates one or more PSA measurements, with or without additional modalities such as digital rectal examination or transrectal ultrasonography. "Asymptomatic" is defined as without symptoms that are highly suspicious for prostate cancer. Many older men have chronic, stable lower urinary tract symptoms (e.g., due to benign prostatic hyperplasia ) that are not generally associated with an increased risk for prostate cancer. As in a previous review for the USPSTF, a broad definition of PSA-based screening was utilized that includes traditional single-threshold PSA testing as well as other PSA-based prognostic measures, such as age-adjusted thresholds, velocity, and doubling time.

Prostate Cancer - Ravinder Mohan 2016-09-28

Prostate cancer is diagnosed commonly in the course of general health screening. Very often it is difficult to tell whether the cancer will be aggressive and lethal or will be so slow growing that it will not affect the patient's survival. Treatment can have a major impact on the patient's health-related quality of life. This book presents cutting-edge research in predicting the behavior of localized and metastatic cancer, targeted treatment of cancer that has spread minimally, response to newer methods of treatment, and rehabilitation of patients.

**Encyclopedia of Cancer** - 2018-10-12

Encyclopedia of Cancer, Third Edition provides a comprehensive, up-to-date overview of the multiple facets of the disease, including research, treatment and societal impact. This new edition comprises 180 contributions from renowned experts who present the latest in Mechanisms, Hallmarks of Cancer, Causes of Cancer, Prevention and Control, Diagnosis and Therapy, Pathology and the Genetics of specific Cancers. Readers will find a comprehensive overview of the main areas of oncology, including etiology, mechanisms, prevention, and treatments, from basic science to clinical applications and public health, all set alongside the latest advances and hot topics that have emerged since the previous edition. Topics of interest in the field, including genomics and epigenomics, our understanding of the causes of cancer and the approaches to preventing it (e.g., HPV vaccination, role of obesity and nutrition, molecular markers of environmental exposures), new screening techniques (e.g., low-dose CT for lung cancer) and improvements in the treatment of many cancers (e.g., breast cancer, lung adenocarcinoma) are comprehensively and authoritatively presented. Comprises 180 contributions from renowned experts who present the latest in mechanisms, hallmarks of cancer, causes, prevention and control, diagnosis and therapy, pathology and genetics Presents a comprehensive overview of the main areas of oncology, including etiology, mechanisms, prevention, and treatments, from basic science to clinical applications and public health

**PSA and Prostate Cancer** - Jake A. Saylor 2010-01

Prostate cancer (PCa) is a disease with high incidence and prevalence. It is the most common non-cutaneous malignancy among men in the U.S. Discovery of prostate specific antigen (PSA) revolutionised screening of PCa which was largely dependent on detection of prostatic and phosphatase and digital rectal examination. This book reviews the use of PSA as a biomarker and the various aspects of the possible role of PSA in prostate cancer. Moreover, the N-glycan structures described in PSA are examined from different origins, such as prostate tumour cell lines, seminal plasma from healthy donors, serum from PCa and prostate BPH patients. This book also sheds light on the potential clinical utility of cell-free DNA for prostate cancer screening, diagnosis and prognosis and assesses the attributes of circulating DNA in its environment. Recent advances and clinical trials in immunotherapy for prostate cancer are highlighted, along with an emphasis on those that employ prostate specific antigen (PSA) as a target. Other chapters evaluate post prostatectomy PSA level and its association with prostate cancer relapse. PSA and signal transduction in Prostate Cancer and PSA in bone metastases and its connection to the immune system are examined as well.

The Oncobiology of the Prostate - D.P. Wood 2000-12-20

Prostate cancer (PCa) is the most common newly diagnosed cancer among men in the United States today. With the advent of the prostate-specific antigen (PSA) test, the number of newly diagnosed cases has increased tremendously. The rates of PCa have increased so dramatically over the last decade that the age-adjusted incidence rate of PCa is no greater than that for any other cancer among men in the United States. Although PCa rates have risen steadily since 1973, there has been a dramatic acceleration in the late 1980s which has been associated with the introduction and use of PSA for screening and early detection. There is now some evidence that the rates may be levelling off and even decreasing in some areas. After lung cancer, PCa is the leading cause of death due to cancer in men in the United States. Although PCa can occur in younger men, it is essentially a cancer of elderly men. The highest rates of PCa in the world occur among African-American men in the United States. African-Americans have higher rates than Caucasians at all age levels in the United States, and adjusting for social-economic status does not appear to account for this difference to any appreciable extent. There is no clear reason why PCa rates are so much greater among African-Americans compared with Caucasians in the United States. The reported rates in Africans are substantially lower than those of an African-American, suggesting that environmental factors have an influence on PCa. In spite of this substantial impact on our society. PCa remains a relatively understudied disease, with an essentially unknown

etiology. The reviews contained in this book are by no means exhaustive. We have, however, attempted to provide information regarding the pathology of prostate cancer, the status of diagnostic and prognostic markers, as well as a discussion of our understanding of the molecular basis for the disease. The biology of prostate cancer is covered with a discussion on the role of apoptosis in prostate cancer and the suggestion of it being the target for new therapeutic development, as well as the role played by integrins and angiogenesis. The status of current therapies, both hormonal and chemotherapy, are also discussed. This volume should provide a useful background for individuals wishing to commence an in-depth understanding of prostate cancer.

**Biopsy Interpretation of the Prostate** - Jonathan I. Epstein 2019-11-11

Part of the highly regarded Biopsy Interpretation Series, this fully revised volume is your definitive guide to mastering biopsy pathology interpretation for prostate cancer care. Biopsy Interpretation of the Prostate, 6th Edition, provides superbly illustrated guidance from a top expert in the field, guiding you through the best utilization of H&E microscopy as well as the latest immunohistochemical markers in order to deliver accurate, reliable diagnoses. Hundreds of full-color illustrations depict the full range of benign and malignant prostatic entities.

*Prostatic Ultrasonography* - Martin I. Resnick 1990

Focusing on the diagnosis of prostate disorders via ultrasound, this work discusses recent advances and techniques, such as transrectal views. Coverage includes prostate cancer, prostate and ultrasound anatomy, benign hyperplasia, inflammatory disease and calculi and male infertility.

**Encyclopedia of Reproduction** - 2018-06-29

Encyclopedia of Reproduction, Second Edition comprehensively reviews biology and abnormalities, also covering the most common diseases in humans, such as prostate and breast cancer, as well as normal developmental biology, including embryogenesis, gestation, birth and puberty. Each article provides a comprehensive overview of the selected topic to inform a broad spectrum of readers, from advanced undergraduate students, to research professionals. Chapters also explore the latest advances in cloning, stem cells, endocrinology, clinical reproductive medicine and genomics. As reproductive health is a fundamental component of an individual's overall health status and a central determinant of quality of life, this book provides the most extensive and authoritative reference within the field. Provides a one-stop shop for information on reproduction that is not available elsewhere Includes extensive coverage of the full range of topics, from basic, to clinical considerations, including evolutionary advances in molecular, cellular, developmental and clinical sciences Includes multimedia and interactive teaching tools, such as downloadable PowerPoint slides, video content and interactive elements, such as the Virtual Microscope

*Accurate Results in the Clinical Laboratory* - Amitava Dasgupta 2019-07-20

Accurate Results in the Clinical Laboratory: A Guide to Error Detection and Correction, Second Edition, provides a comprehensive review of the factors leading to errors in all areas of clinical laboratory testing. This trusted guide addresses interference issues in all laboratory tests, including patient epigenetics, processes of specimen collection, enzymes and biomarkers. Clinicians and laboratory scientists will both benefit from this reference that applies discussions to both accurate specimen analysis and optimal patient care. Hence, this is the perfect reference for clinical laboratorians, from trainees, to experienced pathologists and directors. Provides comprehensive coverage across endocrine, oncology, hematology, immunohistochemistry, immunology, serology, microbiology, and molecular testing Includes new case studies that highlight clinical relevance and errors to avoid Highlights the best titles published within a variety of medical specialties Reviewed by medical librarians and content specialists, with key selections compiled in their annual list